vantuylen

[From Aidsmap,  March 11, 2019] “One in six people not on treatment in a large South African household survey already had drug-resistant HIV and more than half of those on treatment had resistance to at least one drug, researchers reported last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle.” For more, […]

[From Time,  March 11, 2019] “President Donald Trump’s proposed 2020 budget includes nearly $300 million meant to “defeat the HIV/AIDS epidemic” in the U.S. — even as it calls for a 12% reduction in total funding to the Department of Health and Human Services (HHS).” For more, click here.

[From aidsmap,  March 8, 2019] “35% of sexually active gay and bisexual men used PrEP, or pre-exposure prophylaxis, to prevent HIV in 2017, according to a new study from the Centers for Disease Control and Prevention, NBCNews reports.” For more, click here.

[From aidmap,  March 6, 2019] “A daily pill containing the newer formulation of tenofovir in combination with emtricitabine (Descovy)had a comparable protective effect to the existing daily pill which contains the older tenofovir and emtricitabine (Truvada), Dr Brad Hare of the Kaiser Permanente San Francisco Medical Center told the Conference on Retroviruses and Opportunistic Infections (CROI

[From Fortune,  March 5, 2019] “Should a biotech giant holding a valuable patent be forced to give it up if doing so would serve the public good? That’s the mounting debate over Gilead Sciences’ hold on an HIV prevention treatment, which some say is too expensive and should be available to all.” For more, click here.